Deutsche Bank AG decreased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating) by 4.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 363,523 shares of the medical equipment provider’s stock after selling 15,306 shares during the period. Deutsche Bank AG owned 0.17% of Zimmer Biomet worth $46,349,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the stock. HB Wealth Management LLC increased its position in Zimmer Biomet by 4.0% during the fourth quarter. HB Wealth Management LLC now owns 2,371 shares of the medical equipment provider’s stock worth $302,000 after buying an additional 92 shares in the last quarter. 1ST Source Bank increased its position in Zimmer Biomet by 0.7% during the fourth quarter. 1ST Source Bank now owns 13,149 shares of the medical equipment provider’s stock worth $1,676,000 after buying an additional 95 shares in the last quarter. Securian Asset Management Inc. increased its position in Zimmer Biomet by 0.6% during the fourth quarter. Securian Asset Management Inc. now owns 17,176 shares of the medical equipment provider’s stock worth $2,190,000 after buying an additional 100 shares in the last quarter. Ellevest Inc. increased its position in Zimmer Biomet by 9.1% during the fourth quarter. Ellevest Inc. now owns 1,239 shares of the medical equipment provider’s stock worth $158,000 after buying an additional 103 shares in the last quarter. Finally, CI Investments Inc. increased its position in Zimmer Biomet by 13.9% during the fourth quarter. CI Investments Inc. now owns 887 shares of the medical equipment provider’s stock worth $113,000 after buying an additional 108 shares in the last quarter. Hedge funds and other institutional investors own 87.21% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts have recently commented on ZBH shares. Stifel Nicolaus lifted their price objective on Zimmer Biomet from $160.00 to $165.00 in a research report on Thursday, May 18th. Deutsche Bank Aktiengesellschaft lifted their price objective on Zimmer Biomet from $121.00 to $147.00 in a research report on Wednesday, May 3rd. 22nd Century Group reaffirmed a “maintains” rating on shares of Zimmer Biomet in a research report on Thursday, May 18th. Barclays lifted their price objective on Zimmer Biomet from $105.00 to $116.00 in a research report on Thursday, May 4th. Finally, UBS Group started coverage on Zimmer Biomet in a research report on Tuesday, March 28th. They issued a “sell” rating and a $112.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and an average target price of $143.67.
Insider Activity at Zimmer Biomet
Zimmer Biomet Trading Up 0.5 %
Shares of ZBH opened at $136.01 on Friday. The stock’s 50-day moving average is $133.68 and its two-hundred day moving average is $128.13. The stock has a market cap of $28.37 billion, a PE ratio of 63.56, a P/E/G ratio of 2.48 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.39 and a 12 month high of $149.25. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.89 and a quick ratio of 0.93.
Zimmer Biomet (NYSE:ZBH – Get Rating) last issued its quarterly earnings data on Tuesday, May 2nd. The medical equipment provider reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.25. The company had revenue of $1.83 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Zimmer Biomet had a return on equity of 12.43% and a net margin of 6.33%. The firm’s quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.61 earnings per share. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.45 earnings per share for the current fiscal year.
Zimmer Biomet Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Monday, July 31st. Investors of record on Monday, June 26th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date of this dividend is Friday, June 23rd. Zimmer Biomet’s dividend payout ratio is currently 44.86%.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products.
Read More
- Get a free copy of the StockNews.com research report on Zimmer Biomet (ZBH)
- FuelCell Is Back To Realistic Valuation
- MarketBeat Week in Review – 6/4 – 6/9
- Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition
- Tax Software Specialist Vertex In Buy Zone After Base Breakout
- What is a Mutual Fund? How Does it Work?
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
